Femtrace Launch Planned For Early 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Warner Chilcott's hormone therapy clears FDA for the treatment of the vasomotor symptoms of menopause. Approval is not granted for a vulvar-vaginal atrophy indication, however. The company will use part of its 400-person U.S. sales force to market the product.
You may also be interested in...
Warner Chilcott's Low-Dose FemHRT Clears FDA
Company says low-dose FemHRT is "consistent" with hormone replacement therapy guidelines. The drug's second quarter launch could coincide with the introduction of Warner Chilcott's other recently approved hormone replacement therapy, Femtrace.
Warner Chilcott's Low-Dose FemHRT Clears FDA
Company says low-dose FemHRT is "consistent" with hormone replacement therapy guidelines. The drug's second quarter launch could coincide with the introduction of Warner Chilcott's other recently approved hormone replacement therapy, Femtrace.
Warner-Chilcott Back On The Block: Buy-Out Offer Values Firm At $2.7 Bil.
Private equity group has approached company about possible bid. Proposal comes a year after Warner-Chilcott/Galen held negotiations with another pharma company about a merger.